Imperial College London
Alternate

ProfessorEricAboagye

Faculty of Medicine, Department of Surgery & Cancer

Professor
 
 
 
//

Contact

 

+44 (0)20 3313 3759eric.aboagye

 
 
//

Assistant

 

Mrs Maureen Francis +44 (0)20 7594 2793

 
//

Location

 

GN1Commonwealth BuildingHammersmith Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Allott:2020:10.3390/cancers12040865,
author = {Allott, L and Dubash, S and Aboagye, EO},
doi = {10.3390/cancers12040865},
journal = {Cancers},
title = {[18F]FET-βAG-TOCA: the design, evaluation and clinical translation of a fluorinated octreotide},
url = {http://dx.doi.org/10.3390/cancers12040865},
volume = {12},
year = {2020}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - The success of Lutathera™ ([177Lu]Lu-DOTA-TATE) in the NETTER-1 clinical trial as a peptide receptor radionuclide therapy (PRRT) for somatostatin receptor expressing (SSTR) neuroendocrine tumours (NET) is likely to increase the demand for patient stratification by positron emission tomography (PET). The current gold standard of gallium-68 radiolabelled somatostatin analogues (e.g., [68Ga]Ga-DOTA-TATE) works effectively, but access is constrained by the limited availability and scalability of gallium-68 radiopharmaceutical production. The aim of this review is three-fold: firstly, we discuss the peptide library design, biological evaluation and clinical translation of [18F]fluoroethyltriazole-βAG-TOCA ([18F]FET-βAG-TOCA), our fluorine-18 radiolabelled octreotide; secondly, to exemplify the potential of the 2-[18F]fluoroethylazide prosthetic group and copper-catalysed azide-alkyne cycloaddition (CuAAC) chemistry in accessing good manufacturing practice (GMP) compatible radiopharmaceuticals; thirdly, we aim to illustrate a framework for the translation of similarly radiolabelled peptides, in which in vivo pharmacokinetics drives candidate selection, supported by robust radiochemistry methodology and a route to GMP production. It is hoped that this review will continue to inspire the development and translation of fluorine-18 radiolabelled peptides into clinical studies for the benefit of patients.
AU  - Allott,L
AU  - Dubash,S
AU  - Aboagye,EO
DO  - 10.3390/cancers12040865
PY  - 2020///
SN  - 2072-6694
TI  - [18F]FET-βAG-TOCA: the design, evaluation and clinical translation of a fluorinated octreotide
T2  - Cancers
UR  - http://dx.doi.org/10.3390/cancers12040865
UR  - https://www.ncbi.nlm.nih.gov/pubmed/32252406
UR  - http://hdl.handle.net/10044/1/79096
VL  - 12
ER  -
Download